

High interest in Long-Acting Injectable PrEP among Filipina Transfeminine Adults

Arjee Javellana Restar, PhD MPH^{1,2,3*}, Ma Irene Quilantang, MA, ScM^{3,4,5}, Jeffrey Wickersham, PhD, MA^{2,6}, Alex Adia, MPH^{3,7}, John Guigayoma, MPH^{3,4}, Amiel Nazer Bermudez, MD, MPH^{3,8,9}, Omar Galárraga, PhD¹⁰, Dalmacio Dennis Flores, PhD, ACRN^{2,11}, Susan Cu-Uvin, MD^{3,4}, Jennifer Nazareno, PhD^{3,4}, Don Operario, PhD,^{3,12} Olivia Sison, MS, ScM^{3,8,13}

¹ Department of Epidemiology, University of Washington, School of Public Health, Seattle, WA, USA

² Department of Behavioral and Social Sciences, Research Education Institute for Diverse Scholars (REIDS), Yale University School of Public Health, New Haven, CT, USA

³ Philippines Health Initiative for Research, Service & Training (PHIRST), Brown University School of Public Health, Providence, RI, USA

⁴ Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA

⁵ Department of Behavioral Sciences, University of Philippines-Manila, Manila, Philippines

⁶ Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA

⁷ Division of Health Policy and Management, University of California – Berkeley School of Public Health, Berkeley, CA, USA

⁸ Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA

⁹ Department of Epidemiology and Biostatistics, University of Philippines-Manila, Manila, Philippines

¹⁰ Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, USA

¹¹ Department of Family and Community Health, University of Pennsylvania School of Nursing, Philadelphia, PA, USA

¹² Department of Behavioral, Social, and Health Education Sciences. Emory University Rollins School of Public Health, Atlanta, GA, USA

¹³ Institute of Clinical Epidemiology, National Institutes of Health, University of Philippines-Manila, Manila, Philippines

* Corresponding Author

Email: restar@uw.edu

1 **Abstract**

2
3 Transfeminine adults are impacted by the HIV epidemic in the Philippines, and newly approved
4 modalities of pre-exposure prophylaxis (PrEP), including long-acting injectable (LAI-PrEP),
5 could be beneficial for this group. We utilized secondary data from the #ParaSaAtin survey that
6 sampled Filipina transfeminine adults (n=139) and conducted a series of multivariable logistic
7 regressions with lasso selection to explore factors independently associated with PrEP outcomes,
8 including awareness, discussion with trans friends, and interest in LAI-PrEP. Overall, 53% of
9 Filipina transfeminine respondents were aware of PrEP, 39% had discussed PrEP with their trans
10 friends, and 73% were interested in LAI-PrEP. PrEP awareness was associated with being non-
11 Catholic, having previously been HIV tested, discussing HIV services with a provider, and
12 having high HIV knowledge ($p<0.05$). Discussing PrEP with friends was associated with older
13 age, having experienced healthcare discrimination due to transgender identity, having HIV
14 tested, and having discussed HIV services with a provider ($p<0.05$). Interest in LAI-PrEP was
15 associated with living in Central Visayas, having discussed HIV services with a provider, and
16 having discussed HIV services with a sexual partner were associated ($p<0.05$). Implementing
17 LAI-PrEP in the Philippines requires addressing systemic improvements across personal,
18 interpersonal, social, and structural levels in healthcare access, including efforts to create
19 healthcare settings and environments with providers who are trained and competent in
20 transgender health and can address the social and structural drivers of trans health inequities,
21 including HIV and barriers to LAI-PrEP.

22
23 233/300
24

25 **Introduction**

26 Transfeminine adults are disproportionately impacted by the growing HIV epidemic in the
27 Philippines, where the epidemic has grown exponentially over the last decade [1]. Based on
28 successful findings from a PrEP demonstration study in the Philippines showing clinical
29 effectiveness [2], the Philippines' Department of Health recently approved
30 Tenofovir/Emtricitabine (TDF/FTC) as daily oral pre-exposure prophylaxes (PrEP) for HIV
31 prevention [3]. Updated national clinical guidelines now recognize PrEP as part of its national
32 essential medicine formulary as of January 2022 [3], and recommend the urgent need to deliver it
33 to populations placed vulnerably to HIV infection, including Filipina transfeminine adults who
34 are bearing the brunt of the epidemic – with HIV prevalence approximately doubling (3.9% in
35 2020 vs. 1.7% in 2018) within a short timeline [1, 4]. Moreover, with several clinical trials in the
36 pipeline testing new modalities such as long-acting injectable pre-exposure prophylaxes (LAI-
37 PrEP) – including the cabotegravir extended-release injectable suspension formulation that was
38 recently approved by the United States Food and Drug Administration that showed superior
39 efficacy when compared to daily oral PrEP among transfeminine adults [5, 6] – understanding
40 how LAI-PrEP would fit into the lives of transfeminine adults in the Philippines is necessary for
41 future PrEP implementation programs in the country.

42

43 The emerging literature of implementation science, as applied within the field of biomedical HIV
44 prevention [7, 8], emphasizes the need for a critical, formative understanding of multiple
45 determinants across the socio-ecological (e.g., personal, social, community, structural) levels that
46 can guide implementation of LAI-PrEP. In a systematic review synthesizing determinants of
47 PrEP implementation [8], frequent barriers included factors across socio-ecological levels: (a) at

48 the personal level - lack of PrEP awareness and knowledge, adherence challenges to daily
49 medication over time, and concerns about side effects and interactions with other medications
50 such as gender-affirming hormones [9-12]; (b) at the interpersonal level - discomfort talking to
51 providers about PrEP, provider's lack of knowledge or support of PrEP, and having mistrust of
52 providers [13-15]; (c) at the social level -lack of partner support for taking PrEP, and lack of
53 communication about health issues and PrEP among community members [14, 16, 17], including
54 PrEP discussion among trans friends and providers [15]; and (d) at the structural level - having
55 segregated or fragmented health care systems, concern about paying for PrEP including out-of-
56 pocket costs for necessary labs and visit copays, frequency of required clinic visits, stigma and
57 discriminatory practices and policies related to PrEP, HIV, transgender identity, and sexual
58 behavior, as well structural determinants such as poverty, unemployment, unstable housing [14,
59 16-19]. Moreover, while the Philippines is considered one of the most socially tolerant countries
60 for lesbian, gay, bisexual, and transgender (LGBT) people compared to other neighboring
61 countries in the Southeast Asian region [20], its policies and laws continue to reflect transphobia,
62 sexual conservatism, and highly influenced by pervasive religious fundamentalist hegemony [21-
63 23], with 81% of the country's population being affiliated with Catholicism [24].

64

65 Given transfeminine adults' vulnerability to HIV infection in the Philippines as well as the
66 multiple barriers and challenges across the socio-ecological levels in implementing PrEP,
67 understanding promising strategies to deliver new PrEP modalities is vital to its success. While
68 some lessons can be derived from previous PrEP studies, advances in injectable PrEP as a
69 delivery modality could pose unique challenges and barriers to implementation of LAI-PrEP
70 among transfeminine adults in the Philippines, which are necessary considerations for LAI-PrEP

71 program designers and providers to optimize engagement across the PrEP continua (i.e.,
72 awareness, uptake, adherence, and retention) [25-29]. To our team's knowledge, there are
73 currently no studies that specifically examine LAI-PrEP among Filipina transfeminine
74 populations [30]. Given the need for formative studies in LAI-PrEP implementation among
75 Filipina transfeminine adults, the purpose of our exploratory study is to examine prevalence and
76 correlates of outcomes along the PrEP continua, particularly awareness, discussion among
77 friends, and interest in taking LAI-PrEP.

78

79

80 **Methods**

81 **Study Sample and Procedures**

82 We utilized the STROBE checklist for reporting cross-sectional study, which can be found in S1
83 Table.

84

85 This is a secondary data analysis of Filipina transfeminine respondents (n=139) from the
86 #ParaSaAtin project, a cross-sectional online survey conducted between June 2018 to May 2019
87 that examined the social, community, and structural drivers of HIV and factors that impact the
88 utilization of HIV services including PrEP among transfeminine adults in the Philippines. For
89 this analysis, we focused specifically on PrEP awareness, PrEP discussion among trans friends,
90 and interest in LAI-PrEP as outcomes.

91

92 Full study procedures are described elsewhere [31]. Briefly, the study used online convenience
93 sampling recruitment strategies, which included deploying the survey using banners, social

94 media advertisements, and online social groups (e.g., Facebook, Twitter) hosted by local HIV
95 community-based organizations and transgender communities in the Philippines. Participants
96 enrolled in the study were: 18 years or older, transfeminine (i.e, have a gender identity along the
97 transfeminine spectrum such as women, trans women, and with sex assigned at birth as male),
98 had condomless sex within the past year, currently living in Metro Manila and Central Visayas
99 (i.e., the two HIV hotspot areas in the country), and demonstrated English and consent
100 comprehension via a brief cognitive screening form. We utilized multiple best practices for
101 online sampling procedures [32], which include: (1) using a captcha box to eliminate out robots
102 as well as, (2) deactivating ballot stuffing to prevent survey takers from taking the survey more
103 than once. The survey lasted between 20 to 25 minutes, and participants received ₱300 (\$5.85
104 USD) for completing the survey.

105

106 **Measures**

107 **Demographic factors**

108 Participants were asked about their age (18 to 24, 25 to 29, 30 to 34, 35 years or more), current
109 living location (Metropolitan Manila, or Central Visayas), highest education attained (high
110 school and below, some college, or college and beyond), past year income (no income / less than
111 ₱10,000, ₱10,000 to less than ₱20,000, ₱20,000 to less than ₱30,000, ₱30,000 or more),
112 religious affiliation (Catholic, non-Catholic (e.g., Protestant, Christian), or non-religious), and
113 sexual orientation (gay/lesbian, bisexual, straight, or another sexual orientation).

114

115 **Social marginalization factors**

116 Social marginalization included measures specific to homelessness, unemployment, and whether
117 they themselves engaged in sex work. We assessed whether participants had a history of
118 homelessness (yes vs. no), were currently unemployed (yes vs. no), or recently within the past 4
119 months) had engaged in sex work themselves (yes vs. no).

120

121 **Community-level factors**

122 Community-level factors included measures of social cohesion, general and LGBT-specific
123 social participation, and healthcare accessibility. We adapted Lippman and colleagues' social
124 cohesion scale [33], which is comprised of 9 items with 5-point Likert responses (from strongly
125 agree=1 to strongly disagree=5) that measure participants' perceptions of trust and
126 connectedness with their communities, including items such as: "You can count on your friends
127 to help you access health services," and "You can count on your friends to support the use of
128 condoms." Responses were tested for internal consistency (Cronbach $\alpha=0.87$), summed, scored
129 continuously, and split at the median to dichotomize into low vs. high social cohesion categories.
130 We then assessed social participation in general and LGBT community activities by adapting
131 Fonner and colleagues' 4-item social participation scale [34]. Similarly, responses were tested
132 for internal consistency (Cronbach $\alpha=0.75$ for general social participation, and Cronbach $\alpha=0.76$
133 for LGBT social participation, respectively), summed, scored continuously, and split at the
134 median to dichotomize into low vs. high social participation categories. Lastly, we adapted
135 Haggerty and colleagues' 6-item healthcare accessibility scale to assess participant's level of
136 care access (e.g., traveling to their provider's office, waiting times) [35]. Responses ranged from
137 very poor to excellent, and were then tested for internal consistency, (Cronbach $\alpha=0.93$),

138 summed, scored continuously, and split at the median to dichotomize into poor/fair vs.
139 good/excellent accessibility categories.

140

141 **HIV and other healthcare indicators**

142 Participants were asked about their health care history and experiences, including if they have
143 current health insurance, ever took hormones for gender affirmation, ever had surgery for gender
144 affirmation, or experienced healthcare discrimination due to their transgender identity. We also
145 asked about their healthcare history with HIV services, including if they ever had an HIV test,
146 discussed HIV with their provider or sexual partner, or avoided HIV services due to: cost,
147 distance to/from a healthcare facility, their transgender identity, or healthcare facility's lack of
148 LGBT anti-discrimination policy. All responses were either yes or no. Additionally, using the
149 International AIDS Questionnaire, we assessed participants' HIV knowledge. Responses were
150 tested for internal consistency (Cronbach $\alpha= 0.84$), summed, scored continuously, and split at the
151 median to dichotomize into low vs. high HIV knowledge categories [36].

152

153 **PrEP awareness, PrEP discussion among trans friends, and Interest in LAI-PrEP** 154 **(outcomes)**

155 We asked whether participants are aware of PrEP, have had discussions about PrEP with their
156 trans friends, and if they are interested in taking LAI PrEP. These questions were adapted from
157 Restar and colleague's PrEP acceptability study [13]. Specifically, all participants were first
158 provided a brief definition of PrEP: "One way to fight HIV is called PrEP, which stands for pre-
159 exposure prophylaxis. PrEP works by giving HIV- negative people HIV drugs to keep them from
160 getting HIV." To assess for PrEP awareness, we asked participants if they "have heard of HIV-

161 negative people taking HIV medication before sex because they thought it would lower their
162 chances of getting HIV (also known as PrEP)?” We then asked participants if they have had
163 PrEP discussions among their trans friends. Response options for both questions were either yes
164 vs. no. Lastly, we assessed interest in LAI-PrEP by asking, “If the possibility of having a long-
165 lasting injectable drug to prevent HIV (“injectable PrEP”) was available, would you be interested
166 in taking it?” and responses were conservatively recoded and dichotomized to very interested vs.
167 somewhat/not at all interested.

168

169 **Data Analysis**

170 We conducted descriptive analyses (frequencies, percentages) to examine the overall distribution
171 of the final analytic sample (n=139) of Filipina transfeminine adults, and stratified per our
172 outcomes (PrEP awareness, PrEP discussion, and interest in LAI-PrEP). We then performed
173 bivariate analyses to examine patterns of our outcomes across our measured exposure variables
174 (e.g., demographics, social marginalization factors, community factors, HIV and other healthcare
175 indicators).

176

177 To examine characteristics associated with our outcomes (PrEP awareness, PrEP discussion, and
178 interest in LAI-PrEP), we performed a series of multivariate logistic regression analyses. Given
179 the exploratory nature of this study, we utilized lasso regression procedures to identify the key
180 variables per outcome [37]. All variables that were selected via the lasso procedure were
181 included in the final adjusted model per outcome. Additionally, given the modest sample size,
182 we used nonparametric bootstrapping procedures using 100 iterations to reduce Type 1 error per

183 model and estimate confidence intervals [38]. Alpha for analyses was set to <0.05 a priori, and
184 all analyses were conducted using StataMP version 17.0.

185

186 **Ethics**

187 Electronic, written consent forms were obtained from all participants in this study, which
188 provided information about participants' confidentiality, privacy, and voluntary participation in
189 this study. This study acquired approval from Institutional Review Board of the Brown
190 University Brown University Human Research Protection Program (IRB Protocol,
191 #1802001982).

192

193 **Results**

194 **Sample Characteristics**

195 Shown in Table 1, most respondents in the sample were between 25-29 years old (39%), lived in
196 the Metropolitan Manila area (79%), attained college education or beyond (44%), earned less
197 than ₱10,000 or no income in the past year (55%), Catholic (79%), and gay or lesbian (55%). A
198 total of 27% of the sample had ever been homeless, 42% currently unemployed, and 52% had
199 themselves recently engaged in sex work.

200

201 The majority of the respondents had high social cohesion and high LGBT-specific social
202 participation (53% and 57%, respectively). Less than half of the respondents had high general
203 social participation and good/excellent healthcare accessibility (38% and 47%, respectively).
204 Additionally, 32% of respondents had current health insurance, 65% had ever taken gender-

205 affirming hormones, 19% had gender-affirming surgery, and 45% faced healthcare
206 discrimination due to their transgender identity. Most respondents had previously received an
207 HIV test (68%), discussed HIV with their provider (71%) as well as their sexual partner (80%),
208 and displayed high HIV knowledge (50%). About half of the respondents experienced avoidance
209 of HIV services due to: cost (50%), distance to/from a facility (47%), their transgender identity
210 (45%), and lack of LGBT anti-discrimination policy (47%).
211

212
213

Table 1. Study sample characteristics of Filipina transfeminine adults (n=139).

	Total	PrEP Awareness		PrEP Discussion among Trans Friends		Interest in Long-Acting Injectable PrEP	
	n (%)	Yes n (%)	χ^2 test, p-values	Yes n (%)	χ^2 test, p-values	Very Interested n (%)	χ^2 test, p-values
Total	139	74 (53.24)		54 (38.85)		101 (72.66)	
Demographics							
Age							
18 to 24	45 (32.37)	19 (25.68)	\wedge 0.108	9 (16.67)	\wedge 0.014*	35 (36.46)	\wedge 0.255
25 to 29	54 (38.85)	29 (39.19)		27 (50.00)		37 (38.54)	
30 to 34	20 (14.39)	15 (20.27)		9 (16.67)		16 (16.67)	
35 years or more	20 (14.39)	11 (14.86)		9 (16.67)		8 (8.33)	
Current living location							
Metropolitan Manila	110 (79.14)	56 (75.68)	\wedge 0.304	40 (74.07)	0.242	75 (74.26)	\wedge 0.020*
Central Visayas	29 (20.86)	18 (24.32)		14 (25.93)		26 (25.74)	
Highest educational attainment							
High School or below	55 (39.57)	22 (29.73)	\wedge 0.041*	20 (37.04)	\wedge 0.920	36 (35.64)	\wedge 0.319
Some College	23 (16.55)	15 (20.27)		9 (16.67)		18 (17.82)	
College or beyond	61 (43.88)	37 (50.00)		25 (46.30)		47 (46.53)	
Past year income (Philippine Pesos)							
No Income / Less than ₱10,000	77 (55.40)	31 (41.89)	\wedge 0.006**	27 (50.00)	\wedge 0.346	50 (49.50)	\wedge 0.044*
₱10,000 – less than P20,000	27 (19.42)	17 (22.97)		11 (20.37)		24 (23.76)	
₱20,000 – less than P30,000	11 (7.91)	8 (10.81)		7 (12.96)		7 (6.93)	
₱30,000+	24 (17.27)	18 (24.32)		9 (16.67)		20 (19.80)	
Religious affiliation							
Catholic	110 (79.14)	50 (67.57)	\wedge <0.001***	41 (75.93)	\wedge 0.404	79 (78.22)	\wedge 0.545
Non-Catholic (e.g., Protestant, Christian)	21 (15.11)	19 (25.68)		8 (14.81)		17 (16.83)	
Non-religious	8 (5.76)	5 (6.76)		5 (9.26)		5 (4.95)	
Sexual orientation							
Gay / Lesbian	77 (55.40)	41 (55.41)	\wedge 0.866	34 (62.96)	\wedge 0.270	54 (53.47)	\wedge 0.891
Bisexual	18 (12.95)	10 (13.51)		5 (9.26)		14 (13.86)	
Straight	26 (18.71)	15 (20.27)		11 (20.37)		20 (19.80)	
Another sexual orientation	18 (12.95)	8 (10.81)		4 (7.41)		13 (12.87)	
Social Marginalization Factors							
Ever homelessness							

No	101 (73.19)	49 (67.12)	^0.123	36 (67.92)	0.324	71 (71.00)	^0.396
Yes	37 (26.81)	24 (32.88)		17 (32.08)		29 (29.00)	
Currently unemployed							
No	59 (42.45)	53 (71.62)	^<0.001**	33 (61.11)	0.598	39 (38.61)	^0.178
Yes	80 (57.55)	21 (28.38)		21 (38.89)		62 (61.39)	
Recent (<4 mos) sex work engagement							
No	67 (48.20)	41 (55.41)	^0.089	23 (42.59)	0.303	46 (45.54)	^0.344
Yes	72 (51.80)	33 (44.59)		31 (57.41)		55 (54.46)	
Community-level Factors							
Social cohesion							
Low	66 (47.48)	23 (31.08)	^0.010**	16 (29.63)	^0.023*	37 (36.63)	0.047
High	73 (52.52)	51 (68.92)		38 (70.37)		64 (63.37)	
General social participation							
Low	86 (61.87)	39 (52.70)	^0.023*	29 (53.70)	0.114	62 (61.39)	0.848
High	53 (38.13)	35 (47.30)		25 (46.30)		39 (38.61)	
LGBT-specific social participation							
Low	60 (43.17)	20 (27.03)	^<0.001***	16 (29.63)	0.010*	36 (35.64)	0.004**
High	79 (56.83)	54 (72.97)		38 (70.37)		65 (64.36)	
Healthcare Accessibility							
Poor/Fair	74 (53.24)	37 (50.00)	^0.025*	26 (48.15)	0.038*	55 (54.46)	0.085
Good/Excellent	65 (46.76)	37 (50.00)		28 (51.85)		46 (45.54)	
HIV and Other Healthcare Indicators							
Current health insurance							
No	94 (67.63)	40 (54.05)	^<0.001***	29 (53.70)	0.005**	62 (61.39)	^0.014*
Yes	45 (32.37)	34 (45.95)		25 (46.30)		39 (38.61)	
Ever taken hormones for gender affirmation							
No	49 (35.25)	24 (32.43)	0.458	13 (24.07)	0.028*	31 (30.69)	0.076
Yes	90 (64.75)	50 (67.57)		41 (75.93)		70 (69.31)	
Ever had surgery for gender affirmation							
No	112 (80.58)	58 (78.38)	0.485	42 (77.78)	0.506	79 (78.22)	0.338
Yes	27 (19.42)	16 (21.62)		12 (22.22)		22 (21.78)	
Healthcare discrimination due to transgender identity							
No	77 (55.40)	37 (50.00)	0.172	21 (38.89)	0.003**	55 (54.46)	0.716
Yes	62 (44.60)	37 (50.00)		33 (61.11)		46 (45.54)	
Ever had HIV test							

No	45 (32.37)	5 (6.76)	<0.001***	9 (16.67)	0.002**	26 (25.74)	0.006**
Yes	94 (67.63)	69 (93.24)		45 (83.33)		75 (74.26)	
Discussed HIV-services with a healthcare provider							
No	41 (29.50)	4 (5.41)	<0.001***	9 (16.67)	^0.013*	20 (19.80)	<0.001***
Yes	98 (70.50)	70 (94.59)		45 (83.33)		81 (80.20)	
Discuss HIV-services with sexual partner							
No	28 (20.14)	11 (14.86)	^0.137	6 (11.11)	^0.034*	14 (13.86)	0.003**
Yes	111 (79.86)	63 (85.14)		48 (88.89)		87 (86.14)	
HIV knowledge							
Low	69 (49.64)	68 (67.33)	0.541	36 (66.67)	0.626	68 (67.33)	0.470
High	70 (50.36)	33 (32.67)		18 (33.33)		33 (32.67)	
Avoided HIV services due to cost of services							
No	69 (49.64)	49 (48.51)	0.665	27 (50.00)	0.946	49 (48.51)	0.665
Yes	70 (50.36)	52 (51.49)		27 (50.00)		52 (51.49)	
Avoided HIV services due to distance of travel to/from healthcare facility							
No	73 (52.52)	55 (54.46)	0.456	28 (51.85)	0.900	55 (54.46)	0.456
Yes	66 (47.48)	46 (45.54)		26 (48.15)		46 (45.54)	
Avoided HIV services due to transgender identity							
No	76 (54.68)	59 (58.42)	0.149	31 (57.41)	0.606	59 (58.42)	0.149
Yes	63 (45.32)	42 (41.58)		23 (42.59)		42 (41.58)	
Avoided HIV services due to lack of LGBT anti-discrimination policy							
No	73 (52.52)	57 (56.44)	0.132	29 (53.70)	0.823	57 (56.44)	0.132
Yes	66 (47.48)	44 (43.56)		25 (46.30)		44 (43.56)	

214 *p<0.05, ** p<0.01, ***p<0.001

215 ^ Fisher's Exact Test

216 **PrEP Outcomes**

217 As shown in S1 Fig 1, 53% of the sample were aware of PrEP, 39% had discussed PrEP with
218 their trans friends, and 73% were interested in LAI-PrEP.

219

220 **Multivariable logistic regression analyses of PrEP Outcomes**

221 Table 2 shows the final adjusted multivariable logistic regression models with variables selected
222 by lasso procedure per PrEP outcome. Specifically, the first adjusted model (outcome: PrEP
223 awareness) included the following lasso-selected factors: age, past year income, religious
224 affiliation, ever homelessness, current unemployment, general social participation, current health
225 insurance, healthcare discrimination due to transgender identity, ever had HIV test, discussed
226 HIV-services with a healthcare provider, and HIV knowledge. The second adjusted model
227 (outcome: PrEP Discussion among trans friends) included the following lasso-selected factors:
228 age, sexual orientation, recent sex work engagement, LGBT-specific social participation,
229 healthcare accessibility, current health insurance, ever taken hormones for gender affirmation,
230 ever had HIV test, discussed HIV-services with a healthcare provider and with a sexual partner.
231 And lastly, the third adjusted model (outcome: interest in LAI-PrEP) the following lasso-selected
232 factors: currently living location, discussed HIV services with a healthcare provider, and with a
233 sexual partner.

234

235 In the final model of PrEP awareness (Model 1), higher odds of PrEP awareness were associated
236 with respondents who were non-Catholic (adjusted odds ratio [aOR]=1.26, 95% Confidence
237 Interval [CI]=1.04-1.52), had an HIV test (aOR=1.24, 95%CI=1.03-1.49), had discussed HIV

238 services with a healthcare provider (aOR=1.39, 95%CI=1.16-1.68), and had high HIV
239 knowledge (aOR=1.20, 95%CI=1.02-1.41).

240

241 Moreover, higher odds of PrEP discussion among trans friends (Model 2) were associated with
242 respondents who were between 30-34 years older (compared to 18-24 years old) (aOR=1.24,
243 95%CI=1.01-1.55), had experienced healthcare discrimination due to transgender identity
244 (aOR=1.15, 95%CI=1.1-1.33), had an HIV test (aOR=1.40, 95%CI=1.14-1.70), and had
245 discussed HIV services with a healthcare provider (aOR=1.49, 95%CI=1.21-1.84).

246

247 Finally, the odds of being interested in LAI-PrEP (Model 3) were significantly higher among
248 respondents who were currently living in Central Visayas (aOR=1.19, 95%CI=1.01-1.41), had
249 discussed HIV services with a healthcare provider (aOR=1.33, 95%CI=1.13-1.56), and had
250 discussed HIV services with a sexual partner (aOR=1.17, 95%CI=1.08-1.69).

251

252
253
254

Table 2. Results of adjusted multivariable logistic regression with lasso variable selection: Lasso-selected factors associated with PrEP awareness, PrEP discussion among trans friends, and interest in LAI-PrEP.

PrEP Outcomes	Lasso-selected factors	Adjusted OR (95% CI)	p-value
Model 1: PrEP Awareness			
	Age		
	18 to 24	ref	
	25 to 29	1.04 (0.88-1.22)	0.589
	30 to 34	1.19 (0.96-1.48)	0.097
	35 years or more	1.11 (0.89-1.37)	0.331
	Past year income (Philippine Pesos)		
	No Income / Less than ₱10,000	ref	
	₱10,000 – P20,000	1.00 (0.82-1.22)	0.970
	₱20,000 – P30,000	1.14 (0.86-1.50)	0.349
	₱30,000+	1.10 (0.90-1.34)	0.325
	Religious affiliation		
	Catholic	ref	
	Non-Catholic (e.g., Protestant, Christian)	1.26 (1.04-1.52)	0.017*
	Non-religious	0.99 (0.74-1.32)	0.952
	Ever homelessness		
	No	ref	
	Yes	1.13 (0.97-1.32)	0.096
	Currently unemployed		
	No	ref	
	Yes	1.02 (0.86-1.21)	0.747
	General social participation		
	Low	ref	
	High	1.07 (0.93-1.22)	0.312
	Current health insurance		
	No	ref	
	Yes	1.04 (0.89-1.22)	0.566
	Healthcare discrimination due to transgender identity		
	No	ref	
	Yes	1.04 (0.89-1.22)	0.080
	Ever had HIV test		
	No	ref	
	Yes	1.24 (1.03-1.49)	0.023*
	Discussed HIV-services with a healthcare provider		

Model 2: PrEP Discussion among Trans Friends

No	ref	
Yes	1.39 (1.16-1.68)	<0.001***
HIV knowledge		
Low	ref	
High	1.20 (1.02-1.41)	0.021*
Age		
18 to 24	ref	
25 to 29	1.07 (0.91-1.26)	0.366
30 to 34	1.24 (1.01-1.55)	0.040*
35 years or more	1.10 (0.88-1.37)	0.395
Sexual orientation		
Gay / Lesbian	ref	
Bisexual	1.01 (0.80-1.26)	0.921
Straight	1.11 (0.91-1.35)	0.283
Another sexual orientation	0.97 (0.78-1.20)	0.793
Recent (<4 mos) sex work engagement		
No	ref	
Yes	0.94 (0.81-1.10)	0.491
LGBT-specific social participation		
Low	ref	
High	1.02 (0.86-1.21)	0.777
Healthcare Accessibility		
Poor/Fair	ref	
Good/Excellent	0.99 (0.85-1.15)	0.911
Current health insurance		
No	ref	
Yes	1.06 (0.91-1.25)	0.402
Ever taken hormones for gender affirmation		
No	ref	
Yes	0.99 (0.84-1.18)	0.976
Healthcare discrimination due to transgender identity		
No	ref	
Yes	1.15 (1.1-1.33)	0.044*
Ever had HIV test		
No	ref	
Yes	1.40 (1.14-1.70)	0.001**
Discussed HIV-services with a healthcare provider		

Model 3: Interest in Long-Acting Injectable PrEP

No	ref	
Yes	1.49 (1.21-1.84)	<0.001***
Discuss HIV-services with sexual partner		
No	ref	
Yes	0.89 (0.74-1.08)	0.262
Current living location		
Metropolitan Manila	ref	
Central Visayas	1.19 (1.01-1.41)	0.045*
Discussed HIV-services with a healthcare provider		
No	ref	
Yes	1.33 (1.13-1.56)	0.001**
Discuss HIV-services with sexual partner		
No	ref	
Yes	1.17 (1.08-1.69)	0.008**

*p<0.05, ** p<0.01, ***p<0.001, OR=odds ratio, 95% CI=95% Confidence Interval. Each model/outcome ran under a nonparametric bootstrapping procedure with 100 iterations.

256 **Discussion**

257 To our team’s expertise, this is the first study to examine LAI-PrEP outcomes among
258 transfeminine adults in the Philippines. This setting is a compelling national context for
259 understanding the implementation factors to optimize LAI-PrEP, based on the concentrated
260 growth in HIV diagnoses among transfeminine people in the Philippines and the country’s stated
261 commitment to providing PrEP medications to priority populations. Results from this analysis, as
262 discussed below, provide vital insights into future LAI-PrEP studies and programming for this
263 population.

264

265 Notably, all three PrEP outcomes were associated with having a discussion about HIV services
266 with a healthcare provider, reflecting a critical point for future implementation of this
267 intervention. Although the Philippines’ Health Department has articulated a commitment to
268 providing access to PrEP medications for key populations in the Philippines, efforts are needed to
269 train providers in delivering inclusive care for trans populations. Previous research from the
270 Philippines has corroborated the critical importance of non-discriminatory and gender
271 affirmative health settings as the foundation for the delivery of HIV services to transgender
272 people [39]. Additionally, systems are necessary to monitor for trans-discriminatory practices
273 and hold providers and service settings accountable in instances where discrimination and stigma
274 are reported.

275

276 Overall, PrEP awareness was relatively low with just over half of the sample having heard of
277 PrEP. This level of awareness might reflect the very recent approval of PrEP as part of the
278 Philippines government’s medical formulary, with a potential for higher awareness over time.

279 However, research in other settings has noted that PrEP messaging tends to prioritize MSM
280 populations exclusively (e.g., in print and social media campaigns) and has called for the
281 intentional creation of trans-specific messaging to maximize visibility and uptake [16]. Our
282 findings also reveal patterns of PrEP awareness within this transfeminine sample. Of note, those
283 who identified as being Catholic had lower PrEP awareness, suggesting a need to explore the
284 possible roles of stigma and religion as contributors to HIV prevention and risk in this
285 predominantly Catholic setting. Moreover, while many LGBTQ people in the Philippines
286 identify as religious from one recent study [40], the extent to which religiosity and Catholic
287 affiliation dictate sexual behavior and health-seeking behavior specific to sexual health including
288 PrEP is unknown.

289

290 Even fewer participants (39%) had ever discussed PrEP with their friends. Social communication
291 about PrEP has proven to be a challenge in many settings due to PrEP-related stigma in many
292 parts of the world [8]. For example, studies have suggested some of the judgmental beliefs
293 attributed to people interested in PrEP – e.g., beliefs that equate PrEP with promiscuity, risk-
294 taking, shame [41, 42]. Health providers are often viewed as barriers to PrEP due to patients’
295 concerns about stigma when seeking advice about PrEP [42], and due to providers’ lack of both
296 HIV knowledge and trans-specific competency [39]. Indeed, our findings indicated that prior
297 experience of gender-based discrimination in a healthcare setting was negatively associated with
298 PrEP discussion among trans friends. This suggests a need for interventions and support systems
299 that counteract internalized stigma and shame, for example, based on negative health-seeking
300 experiences, and that empower transfeminine people with comfort in openly discussing PrEP as
301 an option for HIV prevention with their peers. These efforts are particularly needed for younger

302 transfeminine people who might lack comfort and experience handling these discussions, as our
303 findings show that those ages 18 to 24 were significantly less likely to discuss PrEP with their
304 peers. Given the lack of comprehensive and LGBTQ-inclusive sex education programming in
305 public schools in the Philippines that may otherwise socialize them to frank discussions with
306 peers about sexuality and sexual health [43-45], it is not surprising to find that younger Filipina
307 transfeminine adults are less to discuss PrEP with trans friends compared to older groups. This
308 finding may also reflect the lack of capacity or comfort to articulate both broad and specific
309 sexuality and sexual health concerns as young adults who may not have disclosed their gender
310 identities or may be newly out. Future HIV education programs for this young adult group must
311 take into account the minimal or total lack of formative experiences they have to discuss LGBTQ
312 sexuality concerns with peers and the skills necessary to develop comfort in these peer-to-peer
313 discussions. As such, one point of further research would be for future interventions to integrate
314 developmentally appropriate and culturally-sensitive peer-led education programs that may be
315 utilized for this subpopulation.

316

317 The majority of the sample reported interest in LAI-PREP thereby indicating a target for future
318 intervention development around this modality. Notably, interest in LAI-PREP was more
319 strongly endorsed by those who had previously discussed HIV services with a sexual partner,
320 suggesting an opportunity for couples-involved strategies to promote this modality as a strategy
321 to promote sexual safety and satisfaction within relationships. Additionally, interest was also
322 stronger among those who were currently based outside of Metro Manila, suggesting the
323 geographic appeal of this long-acting modality among those who might not have proximity to the
324 nation's HIV most resourced hospital and public health settings. Leveraging innovative strategies

325 and lessons learned from the Philippines' local community-based organizations' responses to
326 delivering HIV services in light of the recent COVID-19 pandemic could be promising to
327 integrate into future LAI-PrEP programming [46]; this includes improving logistics and
328 protocols such as online remote service delivery (e.g., counseling, referrals, refill appointments),
329 a continuance of supply chain of medications, and app-based strategies to reach individuals who
330 may be remote or experience travel difficulties to clinics.

331
332 While transfeminine adults in our sample showed high interest in taking LAI-PrEP, it is
333 necessary for future studies aiming to inform PrEP implementation strategies to ascertain what
334 transfeminine adults know about LAI-PrEP, including attitudes and beliefs about LAI-PrEP and
335 how to best deliver it to their communities and social groups [8]. This includes understanding
336 key health communication strategies such as efficacy messaging and framings about LAI-PrEP
337 that resonate with other health priorities among communities of transfeminine adults such as
338 access to hormones and gender-inclusive providers [47]. Future research priorities also include
339 examining preferences for how to best market and package LAI-PrEP with gender-affirming
340 care, along with exploration of other PrEP options and regimens such as daily PrEP, intermittent
341 (2-1-1) dosing, and implants [47, 48] – to ensure that LAI-PrEP fully aligns with and directly
342 benefits Filipina transfeminine adults' goals for HIV prevention and gender-affirmation [49].

343
344 Given that our study only examined three PrEP outcomes (awareness, discussion among friends,
345 and interest), future studies must also expand the scope of examination to other outcomes along
346 the PrEP continua (e.g., awareness, uptake, adherence, and retention) [29], to fully optimize,
347 track, and evaluate the progress of LAI-PrEP implementation programs as it gets delivered at a

348 population-level in the Philippines. This includes formatively understanding and conceptualizing
349 if there are any other unique points or steps to the care continuum that are unique to LAI-PrEP
350 among transfeminine adults.

351

352 Lastly, while findings from adjusted models specific to social marginalization such as
353 homelessness, unemployment, and recent engagement in sex work were not significantly
354 predictive of PrEP outcomes, it is noteworthy for future studies to explore and investigate
355 whether such subpopulations have unique needs specific to LAI-PrEP continuum that may not
356 have been captured in this study. Given the well-recognized role of social marginalization in
357 predisposing communities to higher HIV risks and lower engagement in HIV services [50-52], it
358 is vital for future implementation research to qualitatively explore how LAI-PrEP may be
359 accepted by transfeminine individuals who experience and/or are placed in such socially
360 marginalized settings.

361

362

363 **Limitations**

364 There are several limitations to this study. First, this study is limited in its transferability to other
365 settings in the Philippines due to our recruitment focus on the two largest metropolitan settings in
366 the country. Specifically, in addition to our convenient online sampling, we only recruited in two
367 sites where the HIV epidemic is highly prevalent and only included transfeminine adults. As
368 such, our sample may not capture the diversity of trans communities in the Philippines,
369 particularly those who do not have access to the internet, are not living in the study's recruited
370 areas, or transmasculine and nonbinary adults who are also part of trans communities and are

371 impacted by the epidemic [53]. Second, due to the cross-sectional nature of this study's data
372 collection design, we are unable to ascertain temporal patterns with regard to PrEP outcomes.
373 Lastly, given that our study utilized secondary analysis from an existing dataset, we were unable
374 incorporate additional detailed PrEP-specific outcomes. Future research is necessary to explore
375 socio-ecological factors that are vital in LAI-PrEP implementation in this population and setting.

376

377 **Conclusion**

378 This study provides important foundational work for understanding how LAI-PrEP may fit into
379 the appropriate HIV prevention infrastructure among Filipina transfeminine adults. Though we
380 categorize initial interest in LAI-PrEP, critical other insights will be needed to effectively build
381 towards LAI-PrEP rollout among Filipina transfeminine adults. Building upon these nascent
382 findings, we encourage future work on these fronts, especially moving beyond just research and
383 policy goals and ensuring that other efforts actively engage with community-based organization
384 and their aims and needs. In doing so, the Philippines' HIV response can continue to build
385 towards improvements in equity among transfeminine adults and other impact subpopulations, an
386 important and essential goal.

387

388 **Acknowledgments**

389 We are grateful for all of the Filipina transfeminine participants who took part in this study. This
390 study was supported by the following sponsors: National Institute on Drug Abuse
391 (R36DA048682), the Fogarty International Center (D43TW010565), Providence/Boston Center
392 for AIDS Research (P30AI042853), and the National Institute of Mental Health
393 (R21TW012010). Dr. Restar is a Robert Wood Johnson Foundation Health Policy Research
394 Scholar and a Public Policy Fellow at amFAR, the Foundation for AIDS Research. Drs. Restar,
395 Flores, and Wickersham are supported by the Research Education Institute for Diverse Scholars
396 (REIDS), funded by the National Institute of Mental Health (R25MH087217). This article does
397 not represent the official views of the sponsors.

398 399 **Compliance of Ethical Standards**

400 **Conflict of Interest:** The authors declare that they have no conflict of interest.

401 **Ethical approval:** All procedures performed in studies involving human participants were in
402 accordance with the ethical standards of the institutional research committee (Brown University
403 Ethics Review Board, IRB Protocol, #1802001982) and with the 1964 Helsinki declaration and
404 its later amendments or comparable ethical standards.

405 **Informed consent:** Electronic informed consent was obtained from all individual participants
406 included in the study.

References

1. Joint United Nations Programme on HIV/AIDS [UNAIDS]. UNAIDS Data 2021. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS Available at: https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_enpdf. 2021.
2. PrEPWatch A. Country Updates: Philippines2022.
3. Health Technology Assessment Council - Philippines Department of Health. Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection. Available at: https://bit.ly/HTAC-ES-OralPrEP_Recomm. 2022.
4. Joint United Nations Programme on HIV/AIDS [UNAIDS]. UNAIDS Data 2019 2020.
5. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. *New England Journal of Medicine*. 2021;385(7):595-608.
6. Food U, Administration D. FDA approves first injectable treatment for HIV pre-exposure prevention. FDA gov Updated December. 2021;20.
7. Smith JD, Li DH, Rafferty MR. The implementation research logic model: a method for planning, executing, reporting, and synthesizing implementation projects. *Implementation Science*. 2020;15(1):1-12.
8. Li DH, Benbow N, Keiser B, Mongrella M, Ortiz K, Villamar J, et al. Determinants of implementation for HIV pre-exposure prophylaxis based on an updated Consolidated Framework for Implementation Research: a systematic review. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2022;90(1):S235-S46.

9. Galindo GR, Walker JNJ, Hazelton P, Lane T, Steward WT, Morin SF, et al. Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. *Implementation Science*. 2012;7(1):1-13.
10. Hoagland B, De Boni RB, Moreira RI, Madruga JV, Kallas EG, Goulart SP, et al. Awareness and willingness to use pre-exposure prophylaxis (PrEP) among men who have sex with men and transgender women in Brazil. *AIDS and Behavior*. 2017;21(5):1278-87.
11. Yang D, Chariyalertsak C, Wongthanee A, Kawichai S, Yotruean K, Saokhieo P, et al. Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand. *PloS one*. 2013;8(10):e76650.
12. Bass SB, Kelly PJ, Brajuha J, Gutierrez-Mock L, Koester K, D'Avanzo P, et al. Exploring barriers and facilitators to PrEP use among transgender women in two urban areas: implications for messaging and communication. *BMC public health*. 2022;22(1):1-10.
13. Restar AJ, Kuhns L, Reisner SL, Ogunbajo A, Garofalo R, Mimiaga MJ. Acceptability of antiretroviral pre-exposure prophylaxis from a cohort of sexually experienced young transgender women in two US cities. *AIDS and Behavior*. 2018;22(11):3649-57.
14. Ogunbajo A, Storholm ED, Ober AJ, Bogart LM, Reback CJ, Flynn R, et al. Multilevel barriers to HIV PrEP uptake and adherence among black and Hispanic/Latinx transgender women in southern California. *AIDS and Behavior*. 2021;25(7):2301-15.
15. Restar AJ, Adia A, Cu-Uvin S, Operario D. Characterizing PrEP awareness and interest among Filipina transgender women. *AIDS Education and Prevention*. 2020;32(3):212-28.

16. Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. *Journal of the International AIDS Society*. 2016;19:21105.
17. Sevelius JM, Keatley J, Calma N, Arnold E. 'I am not a man': Trans-specific barriers and facilitators to PrEP acceptability among transgender women. *Global public health*. 2016;11(7-8):1060-75.
18. Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. *AIDS patient care and STDs*. 2013;27(4):248-54.
19. Pacífico de Carvalho N, Mendicino CCP, Cândido RCF, Alecrim DJD, Menezes de Pádua CA. HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review. *AIDS care*. 2019;31(10):1234-40.
20. Flores AR. Social acceptance of LGBT people in 174 countries: 1981 to 2017. 2019.
21. Ross AG, Ditangco RA, Belimac JG, Olveda RM, Mercado ES, Rogers GD, et al. HIV epidemic in men who have sex with men in Philippines. *The Lancet Infectious Diseases*. 2013;13(6):472-3.
22. Reyes MES, Lanic PJP, Lavadia ENT, Tactay E, Tionson ER, Tuazon PJG, et al. Self-stigma, self-concept clarity, and mental health status of Filipino LGBT individuals. *North American Journal of Psychology*. 2015;17(2):343-50.
23. Ruiz Austria CS. The church, the state and women's bodies in the context of religious fundamentalism in the Philippines. *Reproductive health matters*. 2004;12(24):96-103.


24. Lipka M. 5 Facts about Catholicism in the Philippines. Pew Research Center Available from: <https://www.pewresearch.org/fact-tank/2015/01/09/5-facts-about-catholicism-in-the-philippines/#:~:text=About%20eight%2Din%2Dten%20Filipinos,they%20view%20the%20pope%20favorably>. 2015.
25. Kanazawa JT, Saberi P, Saucedo JA, Dubé K. The LAIs are coming! Implementation science considerations for long-acting injectable antiretroviral therapy in the United States: a scoping review. *AIDS Research and Human Retroviruses*. 2021;37(2):75-88.
26. Mantsios A, Murray M, Karver TS, Davis W, Galai N, Kumar P, et al. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials. *BMC health services research*. 2021;21(1):1-14.
27. Lykins WR, Luecke E, Johengen D, van der Straten A, Desai TA. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. *Drug delivery and translational research*. 2017;7(6):805-16.
28. Philbin MM, Bergen S, Parish C, Kerrigan D, Kinnard EN, Reed S, et al. Long-acting injectable ART and PrEP among women in six cities across the United States: a qualitative analysis of who would benefit the most. *AIDS and Behavior*. 2022;26(4):1260-9.
29. Nunn AS, Brinkley-Rubinstein L, Oldenburg CE, Mayer KH, Mimiaga M, Patel R, et al. Defining the HIV pre-exposure prophylaxis care continuum. *AIDS (London, England)*. 2017;31(5):731.

30. Restar A, Nguyen M, Nguyen K, Adia A, Nazareno J, Yoshioka E, et al. Trends and emerging directions in HIV risk and prevention research in the Philippines: A systematic review of the literature. *PloS one*. 2018;13(12):e0207663.
31. Restar AJ, Breslow AS, Jin H, Quilantang MI, Sison O, Bermudez AN, et al. Transgender-specific developmental milestones and associated experiences of violence, discrimination, and stigma among Filipinx transgender women who are sexually active with men. *PLoS one*. 2021;16(3):e0248248.
32. Buchanan EA, Hvizdak EE. Online survey tools: Ethical and methodological concerns of human research ethics committees. *Journal of empirical research on human research ethics*. 2009;4(2):37-48.
33. Lippman SA, Donini A, Díaz J, Chinaglia M, Reingold A, Kerrigan D. Social-environmental factors and protective sexual behavior among sex workers: the Encontros intervention in Brazil. *American journal of public health*. 2010;100(S1):S216-S23.
34. Fonner VA, Kerrigan D, Mnisi Z, Ketende S, Kennedy CE, Baral S. Social cohesion, social participation, and HIV related risk among female sex workers in Swaziland. *PloS one*. 2014b;9(1):e87527.
35. Haggerty JL, Lévesque J-F, Santor DA, Burge F, Beaulieu C, Bouharaoui F, et al. Accessibility from the patient perspective: comparison of primary healthcare evaluation instruments. *Healthcare Policy*. 2011;7(Spec Issue):94.
36. Davis C, Sloan M, MacMaster S, Hughes L. The international AIDS questionnaire—English version (IAQ-E) assessing the validity and reliability. *Journal of HIV/AIDS prevention in children & youth*. 2007;7(2):29-42.

37. Tibshirani R. Regression shrinkage and selection via the lasso. *Journal of the Royal Statistical Society: Series B (Methodological)*. 1996;58(1):267-88.
38. Parra-Frutos I. Controlling the Type I error rate by using the nonparametric bootstrap when comparing means. *British Journal of Mathematical and Statistical Psychology*. 2014;67(1):117-32.
39. Guigayoma J, Bermudez AN, Palatino M, Nazareno J, Cu-Uvin S, Operario D, et al. Responsive Medical Providers and Recent HIV Medical Services Engagement Among Transgender Women and Cisgender Men Who Have Sex With Men in the Philippines. *AIDS Education and Prevention*. 2021;33(6):495-510.
40. del Castillo F, del Castillo CD, Ching G, Campos MS. Centrality of Religiosity among Select LGBTQs in the Philippines. *Religions*. 2021;12(2):83.
41. Golub SA. PrEP stigma: implicit and explicit drivers of disparity. *Current HIV/AIDS Reports*. 2018;15(2):190-7.
42. Hull SJ, Tessema H, Thuku J, Scott RK. Providers PrEP: identifying primary health care Providers' biases as barriers to provision of equitable PrEP services. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2021;88(2):165-72.
43. Gangcuangco LMA. HIV crisis in the Philippines: urgent actions needed. *The Lancet Public Health*. 2019;4(2):e84.
44. Tanaka Y, Araullo GO, Tuliao MT, Yamashita T, Okuda K, Baua EC, et al. The current situation and issues of sexual health education by school nurses in Muntinlupa City, Philippines. *Universal Journal of Public Health*. 2020;8(6):185-92.
45. Iyer P, Clarke D, Aggleton P. Barriers to HIV and sexuality education in Asia. *Health Education*. 2014.

46. Quilantang M, Irene N, Bermudez ANC, Operario D. Reimagining the future of HIV service implementation in the Philippines based on lessons from COVID-19. *AIDS and Behavior*. 2020;24(11):3003-5.
47. Operario D, Restar A. Gender-affirmative systems needed for PrEP implementation. *The Lancet HIV*. 2020;7(12):e799-e800.
48. Celum C, Baeten J. PrEP for HIV prevention: evidence, global scale-up, and emerging options. *Cell Host & Microbe*. 2020;27(4):502-6.
49. Minalga B, Chung C, Davids J, Martin A, Perry NL, Shook A. Research on transgender people must benefit transgender people. *The Lancet*. 2022;399(10325):628.
50. Arrington-Sanders R, Hailey-Fair K, Wirtz AL, Morgan A, Brooks D, Castillo M, et al. Role of structural marginalization, HIV stigma, and mistrust on HIV prevention and treatment among young black latinx men who have sex with men and transgender women: perspectives from youth service providers. *AIDS patient care and STDs*. 2020;34(1):7-15.
51. Hood JE, Eljallad T, Abad J, Connolly M, Heumann C, Fritz J, et al. Getting pre-exposure prophylaxis to high-risk transgender women: lessons from Detroit, USA. *Sexual health*. 2018;15(6):562-9.
52. Brennan J, Kuhns LM, Johnson AK, Belzer M, Wilson EC, Garofalo R, et al. Syndemic theory and HIV-related risk among young transgender women: the role of multiple, co-occurring health problems and social marginalization. *American journal of public health*. 2012;102(9):1751-7.
53. Bumanglag KC. Enhancing HIV/AIDS surveillance in the Philippines to ensure the transgender population's visibility. *American Public Health Association*; 2018. p. 58-60.

S1 Fig. Figure 1. PrEP awareness, PrEP discussion among trans friends, and interest in long-acting PrEP among Filipina transfeminine adults (n=139).



medRxiv preprint doi: <https://doi.org/10.1101/2022.08.02.22278323>; this version posted August 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).